SØBORG, Denmark, April 15, 2024 (GLOBE NEWSWIRE) — Cbio A/S – A pioneer in next-generation T-cell therapies for solid tumors, announces financial results for 2023 and recent company updates.
Cbio A/S, a developer of T-cell therapies, presents its 2023 annual report as part of preparations for clinical trials and announces the transition to the clinical phase with secured funding of DKK 40 million.
